Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNeOCT: Octreotide LAR in Neuroendocrine Tumors
NCT04129255Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of octreotide in neuroendocrine tumors (NETs), sponsored by National Cancer Institute. Started Jun 2017; status: completed.
02
Drugs
octreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04129255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129255.